

1 **Spacer sequences separating transcription factor binding motifs set enhancer quality**
2 **and strength**

3

4 Marion Guérault-Bellone¹, Kazuhiro R. Nitta², Willi Kari^{2, 3}, Edwin Jacox^{1,2}, Rémy Beulé
5 Dauzat¹, Renaud Vincentelli⁴, Carine Diarra¹, Ute Rothbacher^{2, 3}, Christelle Dantec¹,
6 Christian Cambillau⁴, Jacques Piette^{1#} and Patrick Lemaire^{1#}

7

8 (1) Centre de Recherche en Biologie cellulaire de Montpellier, UMR 5237, CNRS-Université
9 de Montpellier, 1919 route de Mende, 34293 Montpellier, France

10 (2) Institut de Biologie du Développement de Marseille- IBDM, UMR7288 CNRS - Aix-
11 Marseille Univ. - Case 907, 163 Avenue de Luminy 13288 Marseille CEDEX 09 FRANCE

12 (3) Current address: Department of Evolution and Developmental Biology, Zoological
13 Institute, University Innsbruck, Technikerstrasse 25, A-6020 Innsbruck, Austria.

14 (4) Architecture et Fonction des Macromolécules Biologiques-AFMB - UMR7257 CNRS -
15 Aix-Marseille Univ. - Case 932, 163 Avenue de Luminy 13288 Marseille CEDEX 09
16 FRANCE

17

18 # Equal contribution and authors for correspondence

19

20 **ABSTRACT**

21 Only a minority of the many genomic clusters of transcription factor binding motifs (TFBM)
22 act as transcriptional enhancers. To identify determinants of enhancer activity, we randomized
23 the spacer sequences separating the ETS and GATA sites of the early neural enhancer of the
24 tunicate *Ciona intestinalis* *Otx* gene. We show that spacer sequence randomization affects the
25 level of activity of the enhancer, in part through distal effects on the affinity of the
26 transcription factors for their binding sites. A possible mechanism is suggested by the
27 observation that the shape of the DNA helix within the TFBM can be affected by mutation of
28 flanking bases that modulate transcription factor affinity. Strikingly, dormant genomic
29 clusters of ETS and GATA sites are awakened by most instances of spacer randomization,
30 suggesting that the sequence of naturally-occurring spacers ensures the dormancy of a
31 majority of the large reservoir of TFBM clusters present in a metazoan genome.

32

33 **Keywords**

34 *Ciona intestinalis*, gene regulation, development, enhancer, transcription factor, DNA shape,
35 Ets, Gata, Otx, ascidian, transcription factor affinity

36

37 **INTRODUCTION**

38 Enhancers play a fundamental role in development, homeostasis, evolution and disease (1, 2).
39 They act as scaffolding platforms for transcription factors and are generally composed of
40 clusters of several binding sites for at least two transcription factors (3). The degree of
41 constraints on the spacing, order and orientation of transcription factor binding sites is
42 variable, with a majority of enhancers active during animal development showing little
43 constraints (4). In spite of this apparent flexibility, we do not understand the determinants of
44 enhancer activity and it remains very difficult to rationally engineer synthetic enhancers from
45 the sole knowledge of upstream transcription factor binding sites (5).

46 The a-element of the ascidian *Ciona intestinalis* is one of the best-characterized chordate
47 enhancers (6–9). This short (55 bp) enhancer drives the embryonic expression of the *Otx* gene
48 from the late 32-cell stage in two animal neural lineages, a6.5 and b6.5 (Figure 1A), in
49 response to the FGF9/16/20 neural inducer (6). This element is also weakly active in the
50 posterior muscle lineage (B6.4) and in the neural progeny of the a6.7 cell pair, two territories
51 that also express *Otx* (Figure 1A).

52 The *cis*-regulatory logic driving the activity of this element in neural lineages has been
53 characterized in detail (Figure 1B). Two maternal transcription factors, Ets1/2 and Gata4/5/6,
54 cooperate to mediate FGF inducibility and tissue specificity, respectively (6,7). Binding of the
55 ubiquitous Ets1/2 transcription factor to its sites drives expression in FGF-responding cells
56 across all germ layers, while binding of the animal determinant Gata4/5/6 restricts this
57 activation to the animal territories (Figure 1B). Mutational inactivation of individual ETS and
58 GATA sites indicate that binding of Gata4/5/6 and Ets1/2 to two sites each is crucial for a-
59 element activity (Figure 1C; 8).

60 The spacing and orientation of ETS and GATA binding sites does not seem to play a major
61 role in a-element activity (8). In spite of this apparent flexibility, only a minority of the
62 numerous *Ciona* genomic clusters containing at least 2 ETS and 2 GATA binding motifs have
63 enhancer activity (8). A recent study of the a-element proposed that the major determinants of
64 enhancer activity are included in the octamers composed of the core recognition tetramer for
65 Ets1/2 (GGAA) and Gata4/5/6 (GATA) flanked by two adjacent nucleotides on either side
66 (9). Dinucleotide repeat motifs required for enhancer function in addition to the transcription
67 factor motifs were also characterized in *Drosophila* (10). In addition, transcription factor
68 binding is, in part, determined by nucleotides lying outside of the DNA sequence directly
69 contacted by the factor (11-14). Here, we combine *in vivo* and *in vitro* studies in a thorough
70 analysis of the sequence determinants of the activity of the a-element enhancer and of other
71 *Ciona* potential early neural enhancers responding to the same *cis*-regulatory logic.

72 **RESULTS**

73 **Contribution of the bases contacted by Transcription Factors to enhancer activity**

74

75 Our aim was to determine the respective roles of transcription factor binding sites and spacer
76 sequences in a-element enhancer activity. For the sake of simplification, we used an a-
77 element variant in which the G2 site was inactivated by point mutation, as this site was shown
78 to be dispensable for enhancer activity (Figure 1C; 8). We first analysed the influence of the
79 stretch of DNA directly contacted by Ets1/2 and Gata4/5/6 on the *in vivo* enhancer activity of
80 the a-element. Published crystal structures for mammalian homologs bound to DNA
81 (Supplementary Figure 1) suggest that Gata4/5/6 directly contacts 6 nucleotides: a central
82 “GATA” core motif flanked on either side by one nucleotide (14, 15, 16). The contacts
83 established by Ets1/2 span 7 nucleotides centered on GGA (17, 18, 19). To assess the relative
84 importance of the nucleotides flanking the invariant “GGA” core of E2 and the “GATA” core
85 of G3 (Figure 1C) we compared the activity of several combinations of point mutations by
86 scoring LacZ staining in the a6.5 and b6.5 lineages in 112-cell stage embryos electroporated
87 with reporter constructs (Figure 1D, E; see material and methods).


88 As expected, changes in the sequences of E2 and G3 quantitatively affected activity levels of
89 the a-element in a6.5 and/or b6.5 lineages, while qualitatively preserving its spatial pattern of
90 activity (not shown). In response to alteration of either binding site, the output levels of
91 variant enhancers ranged from an almost complete inactivity to stronger than WT levels
92 (Figure 1D, E; blue bars).

93 Surprisingly, k-mer based *in silico*-predicted affinities of the E2 and G3 variant octamer sites,
94 derived from Selex-seq data (MOTIF scores see Supplementary Figure 2 and 3), do not
95 necessarily reflect the *in vivo* activity of the variant enhancer (Figure 1D, E; red bars). This
96 was particularly striking for the G3 site mutants, for which very different levels of activity
97 were obtained although predicted affinity scores were undistinguishable. Thus, a-element *in*

98 *in vivo* enhancer activities are only partially explained by the *in silico* predicted affinities of the
99 binding sites for their transcription factors. There was a high correlation between the *in silico*
100 and the *in vitro* relative affinities of Ets1/2 and Gata4/5/6 for the mutated binding sites we
101 tested, as determined by the quantitative multiple fluorescence relative affinity assay
102 (QuMFRA) (Supplementary Figure 4, 5; 20). Thus, we conclude that altered *in vitro* affinity
103 cannot provide a sufficient explanation for the observed effects of the point mutations on
104 enhancer activity (Figure 1D and E).

105 Consistently, out of 14 genomic clusters of 2 ETS and 2 GATA sites with *in silico* predicted
106 affinity scores for their cognate factor at least as good as the a-element, only two, N83 and
107 N26, behaved as enhancers (Supplementary Table 1). The activity of these two elements was
108 restricted to the early neural lineages. Conversely, out of 19 clusters tested by Khoueiry and
109 colleagues (8), inactive cluster C39 has higher *in silico* scores for all its transcription factor
110 binding sites than those of the a-element, while active C35 has 3 weaker scoring transcription
111 factor binding sites. Thus, high *in silico* predicted octamer transcription factor binding sites
112 affinity is not sufficient to explain neural enhancer activity of genomic clusters of ETS and
113 GATA sites.

114



115

116 **Figure 1: Influence of point mutations of the E2 and G3 sites on *in silico* transcription**
 117 **factor binding scores and *in vivo* enhancer activity**

118

119 A) 32-cell stage embryo with cells in which the a-element is strongly (blue) or weakly active
 120 (light blue for neural and pink for muscle lineage). B) Neural induction of the a-element by
 121 the combined activity of Gata4/5/6 and Ets1/2. See text for details. Adapted from (6). C) a-
 122 element sequence showing the mutations in the ETS (blue) and GATA (green) sites tested *in*
 123 *in vivo*. The inactivated (G>A in red) G2 site is in grey. M stands for A or C, W for T or A, H
 124 for A, T or C and N for any base. D) Effect of E2 mutations. Comparison of relative *in vivo*
 125 enhancer activity in two independent experiments (two shades of blue) and *in silico* predicted
 126 binding (red) of Ets1/2 for the E2 mutants. E) Effect of G3 mutations. Comparison of relative
 127 *in vivo* enhancer activity in two independent experiments (two shades of blue) and *in silico*
 128 predicted binding (red) of Gata4/5/6 for the G3 mutants. Activity is relative to the WT a-
 129 element.


130 **Spacer sequences strongly affect enhancer activity**

131

132 As neither the arrangement (8) nor the sequences of transcription factor recognition sites fully
133 explain enhancer activity, we next tested whether the stretches of nucleotides located between
134 transcription factor binding sites, subsequently called spacers, affect enhancer activity. We
135 constructed a library of synthetic enhancers: each randomized variant shared with the a-
136 element the six bases centered on the “GATA” and “GGAA” core sequences of the four
137 GATA- and ETS-binding sites, respectively, as well as the orientation and spacing of these
138 sites. All spacer sequences were, however, fully randomized, the four bases being
139 equiprobable at each position. The *in vivo* enhancer activity of 34 randomized a-elements
140 (Supplementary Figure 6A; Supplementary Table 2) was determined by electroporation as
141 above.

142 While a large majority of naturally occurring genomic clusters of putative ETS and GATA
143 sites are inactive, 25 out of 34 randomized a-element variants had an activity higher or equal
144 to 10% of the wild-type activity, and were considered active (Figure 2). These enhancers
145 displayed a wide range of activity levels with 11 of the variants being at least as active as the
146 original a-element. Spacers are thus quantitative regulators of enhancer activity. The activity
147 of these variants was mostly restricted to a6.5 and b6.5 lineages. In addition, most variants
148 with higher activity than the WT enhancer, as well as three variants with lower activity,
149 showed weak activity in other cell lineages, in which the a-element is weakly active, mainly
150 neural plate and muscle cells (Figure 2 and Supplementary Figure 7). As expected, inhibition
151 of the FGF-signalling pathway by treatment of electroporated embryos with the MEK
152 inhibitor U0126 starting from the 16-cell stage, led to a loss of activity of the variant
153 enhancers (Supplementary figure 8).

154 Taken together, these experiments establish a crucial role for spacer sequences in enhancer
 155 activity: they quantitatively modulate a-element enhancer activity levels, while qualitatively
 156 preserving spatial responsiveness of the element to the FGF pathway.



157

158 **Figure 2: Randomizing the spacer sequences have major effects on the enhancer activity**
 159 **of the a-element of the Otx enhancer**

160

161 A) The sequence of the a-element with randomized bases represented by N and the conserved
 162 GATA motifs boxed in green and ETS motifs in blue, the arrow pointing to their orientation .

163 B) *In vivo* enhancer activity for 34 randomized variants normalized by the wild type enhancer
 164 activity in matching experiment. At least two independent experiments are shown for each
 165 construct. Blue bars correspond to exclusive expression in a6.5 and b6.5 lineages, red bars to
 166 additional expression in a6.7, B6.4 and other lineages.

167

168 **Randomized a-element variants with low *in vivo* activity have decreased *in vitro* affinity**

169 **for Ets1/2 and Gata4/5/6 compared to high activity variants**

170


171 To assess the influence of spacer sequences on the binding of Ets1/2 and Gata4/5/6 to the a-

172 element we turned to *in vitro* binding experiments. We selected 9 randomized variants with

173 equal or higher activity levels than the a-element and 9 variants with undetectable or very low

174 activity (Figure 3A). Using the QuMFRA assay (21), we determined the relative *in vitro*

175 binding affinities of the transcription factors for each of the complete enhancer variants
176 (Supplementary Figure 4). Active variants showed significantly higher *in vitro* binding for the
177 combination of Ets1/2 and Gata4/5/6 proteins than low activity variants (paired t-test,
178 $p=0.001$) (Figure 3B). Both Ets1/2 and Gata4/5/6 proteins individually contributed to the
179 binding preference for active enhancers, with a significantly higher contribution for Ets1/2
180 (paired t-test, p-value of 0.02327 for Ets1/2 compared to 0.05347 for Gata4/5/6;
181 Supplementary Figure 9B).



182
183
184
185
186
187
188
189
190
191
192

Figure 3: Active randomized enhancer variants have a higher *in vitro* affinity for Ets1/2 and Gata4/5/6

A) Relative *in vivo* activities of variant a-elements compared to the WT. Red: inactive variants. Blue: active variants. The right panel provides a populational description of activities. The two populations are different (paired t-test, $p=2.825e-09$). B) Relative *in vitro* binding of Ets1/2+Gata4/5/6 to the same variant a-elements as in A, compared to the WT. The right panel provides a populational description of binding. The two populations are different (paired t-test, $p=0.001$)

193 We conclude that spacer sequences affect the *in vitro* binding of Ets1/2 and Gata4/5/6
194 transcription factors to the enhancers. This could at least partly explain the wide range of
195 enhancer activity levels obtained with the randomized variants.

196

197 **Flanking sequences modulate the affinity of Ets1/2 and Gata4/5/6 for their binding sites**

198

199 We then analysed the individual sites in more detail in order to better understand the spacer
200 effect on transcription factor affinity. First, we compared the binding of Ets1/2 and Gata4/5/6
201 to individual sites and to the complete enhancer of 9 variants (Supplementary figure 10 and
202 Supplementary table 3). We note that binding to the individual sites mostly reflects binding to
203 the complete enhancer, indicating that most information for binding of the transcription
204 factors to the randomized variants is contained within the 30 bp sequence centered on their
205 binding sites, with two exceptions: aR30 E1 site is a high affinity binding site although Ets1/2
206 is poorly binding to the complete enhancer, aR43 E1 and E2 sites are low affinity binding
207 sites although Ets1/2 is strongly binding to the complete enhancer, possibly via a novel ETS
208 site (E3) created in a randomized spacer sequence.

209 Farley and colleagues proposed that the activity of the enhancers is primarily determined by
210 the two bases flanking each side of the “GGAA” or “GATA” core motif sequences (9). We
211 note, however, that in our experiments active variant aR_30 and inactive variant aR_70 share
212 very similar 8 bp-extended ETS and GATA sites, suggesting that additional bases of the
213 spacers contribute to the spacer effect on affinity (Supplementary Figure 6A). To differentiate
214 the effects of proximal bases immediately flanking the transcription factor binding sites to
215 that of more distal effects, we focused on ETS sites, since the ETS sites displayed the most
216 variable affinities.


217 We first tested a 10 bp binding site by keeping 10 bp of the randomized variants centered on
 218 the 6 bp core and completing the fragment with wild type flanking sequences to obtain a 30-
 219 mer (see oligonucleotide aRn-E1/E2s in Figure 4A). Ets1/2 demonstrated very different
 220 affinities for individual variants (Figure 4B). Importantly, sites with identical core octamers
 221 showed different affinities. For instance, the core octamer “TAGGAAAT” is present in both
 222 the high affinity aR9_E2 and the low affinity aR30_E2 sites, while the core “GCGGAAGG”
 223 is present in both the high affinity aR19_E1 and the low affinity aR5_E1 and aR43_E1 sites
 224 (Supplementary table 3). Thus, the observed affinities cannot be explained by the core
 225 octamer only, although the protein is not known to contact bases beyond this motif.

A

```

WT_E2      AAGTTTTCGA AAAGGAAATT GTTCAATATT
aRn-E1/E2s AAGTTTTCGA NNMGGAAARNN GTTCAATATT
aRn-E1/E2  NNNNNNNNNN NNMGGAAARNN NNNNNNNNNN
                12345678
    
```

B



226

227 **Figure 4: Sequences flanking the core octamer modulate the affinity for Ets1/2**

228 A) Fragments used in the gel shift experiments. WT sequences are in black, randomized
 229 sequences are in blue. M is A or C, R is G or A, N is any base. B) Relative affinities of Ets1/2
 230 for the transcription factor binding sites (aRn-E1/E2s) represented in (A) are with respect to in
 231 the 30 bp a-element fragment centered on Ets binding site E2 (WT-E2). Binding sites of
 232 active enhancers are in blue, binding sites of inactive enhancers are in red. Binding sites
 233 sharing the same octamer core are indicated with arrows of the same colour.

234 **Role of position -1 of ETS sites and shaping of the DNA helix**

235




236 Consistently, mutation of the two base pairs flanking the common GCGGAAGG octamer of

237 the aR5 and aR19 variants (Figure 5A) revealed that sites with a purine in position -1 display

238 strong *in vitro* affinity for Ets1/2, while sites with a C in the same position have only weak or

239 no detectable affinity. The identity of the base pair at position +9 was less important, although

240 we noticed a decreasing affinity A>C>G>T.



241
242

243 **Figure 5: Essential role of position -1 in setting ETS affinity and in shaping the DNA**
244 **helix**

245
246 A) Effect on *in vitro* binding affinity to Ets1/2 of systematic mutagenesis of positions -1 and
247 +9 (red) of aR5 and aR19 E1 binding site, which share a common octamer (bold). 10 bp
248 flanking the E2 site of the WT a-element were added on either side of the test decamers. The
249 red arrow points to the aR5 decamer, the blue one to the aR19 decamer. aR5-19-XY has an X
250 in position -1 and a Y in position +9. Affinity is relative to WT-E2 as in Figure 4. B)
251 Predicted roll angle with DNA shape for the oligomers with N = A, C, G or T in position -1 as
252 indicated and A in position 9. ETS site is numbered as in figure 1C. Arrow indicates position
253 between bp -1 and 1. C) Boxplot of predicted roll angles in degrees (Y-axis) for high affinity
254 ETS sites left and Low affinity ETS sites right. Roll angles between consecutive base pairs
255 between position 1 and 9 of ETS site in green. Roll angles between bases -1 and +1 are shown
256 in red.
257

258 The crucial role of position -1 is further stressed by the fact that *in silico* affinity predictions
259 based on Selex-seq data are improved by considering a 9-mer including the -1 position,
260 instead of 8-mers (Supplementary figure 11). Addition of the +9 position does not improve
261 the overall correlation (not shown).

262 Transcription factors recognize their target sequences by reading both the DNA sequence and
263 the shape of the double helix (14). The failure of *in silico* prediction of transcription factor
264 binding affinity to reliably account for enhancer activity when only the identity of the directly
265 contacted base pairs are taken into consideration, suggests that the spacers may affect
266 transcription factor binding distally through a change in the shape of the DNA helix over the
267 TFBM nucleotides directly contacted by the Ets1/2 DNA binding domain (22). Interestingly,
268 the presence of a purine at -1 leads to a negative roll between base pairs -1 and 1 as
269 determined by DNA shape modelling, the roll representing the angle between two consecutive
270 base pairs (Figure 5B) (21). All the high affinity tested sites had a negative roll, while the low
271 affinity sites had a more variable distribution (Figure 5C). Thus, spacer sequences flanking
272 the transcription factor binding site can modify the shape of the DNA helix at the
273 transcription factor binding site, which may alter the affinity of Ets1/2 binding.


274

275 **More distal spacer sequences also affect the affinity of Ets1/2 binding**

276

277 To assess whether the decamer bridging bp -1 and 9 is sufficient to explain the observed
278 affinities or whether the more distally sequences can also contribute, we compared the *in vitro*
279 affinities of the variant decamer ETS sites in the wild-type context (aRn-E1/E2s) to that of the
280 complete variant 30-mer fragments (aRn-E1/E21 in Supplementary Figure 12). Indeed, further
281 addition of spacer sequences at both sites of the decamer modifies the affinity of 5 of the 7
282 tested ETS binding sites (Supplementary Figure 12).

283 To analyze the relative roles of proximal and distal spacer sequences on transcription factor
284 affinity, we replaced the E1 site decamer of the inactive aR5 variant by that of the active aR19
285 variant and *vice versa* and analyzed their *in vitro* interaction with Ets1/2 (Figure 6). The aR5
286 E1 core decamer conserved its low affinity in the aR19 context (aR5Ctx19) while the aR19
287 E1 core decamer in the aR5 context (aR19Ctx5) displayed a reduced affinity for Ets1/2
288 compared to its original context (Figure 6). Thus, while the identity of the two base pairs
289 flanking the core octamer is important for the protein-DNA interaction *in vitro*, flanking
290 sequences can further modulate a favourable combination.



291

292 **Figure 6: Role of sequences immediately flanking or more distantly located from the E1**
293 **core octamer.**

294

295 Comparison of *in vitro* Ets1/2 binding affinities to indicated decamers (Ctx=context). The
296 sequences of the oligonucleotides used for the Gel Shifts are shown above the diagram. The
297 invariant octamer core is in black, aR5 sequences in blue and aR19 sequences in red. Affinity
298 is relative to WT-E2 as in Figure 4.

299

300 We conclude that although the two bases immediately flanking the Ets1/2 core octamer pairs
301 can modify substantially the affinity of the factor, more distant flanking sequences also
302 modulate this affinity.

303


304 **Activation of transcriptionally dormant clusters of ETS and GATA sites by**
305 **randomization of spacer sequences**

306

307 To test whether the major effect of spacer sequences on enhancer activity levels was a
308 specific feature of the very compact a-element, we randomized the spacer sequences of a
309 larger active genomic ETS and GATA cluster, N26 (Supplementary Table 2), whose sites
310 spacing and orientation also differ from the a-element (Supplementary Figure 6B). Similar
311 results (9/13 variants active in the neural lineages) were obtained with N26, suggesting that
312 the contribution of spacer sequences to enhancer activity is not a specific property of the
313 compact a-element (Figure 7A).

314 Most naturally occurring genomic clusters of ETS and GATA sites are transcriptionally
315 inactive. To assess whether this inactivity could be due to inappropriate spacer sequences, we
316 tested the effect of randomizing the spacers of two inactive genomic clusters. One, N61, has
317 naturally occurring high scoring *in silico* recognition sequences for both factors. The second,
318 C53 Opt, results from the optimization of the transcription factor binding sites of an inactive
319 cluster C53. C53 Opt has itself no activity (8). Strikingly, spacer randomization conferred
320 early neural enhancer activity to most variants of the two clusters (5/10 and 9/9 variants
321 respectively) (Figure 7B, C; supplementary figure 6 C, D). We conclude that the inactivity of
322 the tested genomic ETS and GATA clusters is due to inappropriate spacer sequences and that,
323 very surprisingly, most randomized spacer sequences support enhancer function. This
324 suggests that, although, by default, clusters of ETS and GATA binding motifs act as

325 enhancers, most naturally occurring genomic clusters are kept inactive by inappropriate spacer
 326 sequences.



327

328 **Figure 7: Randomization of spacer sequences activates inactive genomic clusters**

329 Organization (top), and *in vivo* activity of three WT or randomized genomic clusters. A)
 330 Active genomic cluster N26. Variants R1, 6, 12, 21, 22, 24, 26, 27 and 28 are considered
 331 active. B) Inactive cluster N61. Variants 14, 15, 16, 111 and 112 are considered active. C)
 332 TFBM-optimized inactive cluster C53. All variants are active. For each set of elements,
 333 results of two independent electroporation experiments are shown. Blue and green arrowheads
 334 respectively represent the position and orientation of ETS and GATA sites, whose sequences
 335 appear below. Blue bars correspond to exclusive expression in a6.5 and b6.5 lineages, red
 336 bars to additional expression in a6.7, B6.4 and other lineages. The activity shown is relative to
 337 the activity of the a-element in the same experiment.

338

339

340 **DISCUSSION**

341

342 In this study, we focused on the features able to confer activity to short clusters of ETS and
343 GATA sites, and in particular to an early *Otx* neural enhancer in *Ciona intestinalis*, the a-
344 element. Our previous work established that, in this element, the order and spacing of ETS
345 and GATA sites was not a critical determinant of enhancer activity, yet that only a small
346 minority of naturally occurring genomic clusters of such sites displayed enhancer activity (8).
347 Thus, while dense clustering of transcription factor binding motifs has been proposed to
348 explain enhancer activity (24), the fact that most genomic clusters of ETS- and GATA-
349 binding motifs are transcriptionally inactive implies additional constraints. These could be
350 provided by the chromosomal or chromatin environment (25) or by highly local sequence
351 features independent of the binding motifs (25, 8). A repressive chromatin environment is
352 unlikely to explain the lack of activity of most tested ETS and GATA clusters, since these
353 short (<130 bp) elements were all tested outside of their normal genomic context and in the
354 context of the same reporter vectors. Local features within the cluster sequences, and
355 independent of TFBMs, were more likely (8).

356 These results prompted us to assay in the present work the activity of libraries of variants of
357 clusters of ETS and GATA sites, in which individual bases of the TFBMs or the whole spacer
358 sequences were systematically mutated. The main results presented here demonstrate that
359 spacer sequences have a strong quantitative impact on enhancer activity, which in its
360 magnitude is as strong as mutations in bases flanking the core nucleotides of TFBMs.
361 Consistently, spacer activity can in part be attributed to modulations of *in vitro* binding of the
362 transcription factors to their cognate TFBMs. This modulation involves bases located at a
363 distance from the bases contacted by the transcription factors. These distal sequences may

364 indirectly affect the shape of the DNA helix within the TFBMs. Finally, we found that in most
365 cases, replacement of natural spacers by randomized ones suffices to confer enhancer activity
366 to inactive genomic clusters of ETS and GATA sites, which may point to an unexpected
367 mechanism to ensure that the majority of clusters born by chance in the genome are kept
368 silent.

369

370 **A role for spacer sequences in the definition of enhancers in metazoan genomes.**

371

372 A recent report by Farley and colleagues analysed the activity of a large number of
373 randomized variants of a slightly different version of the *Otx* a-element in *Ciona* (9) and
374 concluded that the essential information for enhancer activity is included in octameric ETS
375 and GATA sites. The authors did not detect a major role for spacer sequences, but this may
376 reflect the different design of the two studies. Farley et al. only kept the four base pair core
377 sequences for the two ETS and three GATA sites unchanged. The randomization thus affected
378 both bases directly contacted by the transcription factors and directly flanking the core
379 nucleotides, and the spacers as defined in our study. This strategy was therefore able to pick
380 up both determinants of TFBM affinity to their transcription factors, which were the main
381 interest of the authors, and spacer features. A closer analysis of their data indicates that sub-
382 selections of their synthetic enhancers containing binding sites whose predicted *in silico*
383 affinity for ETS and GATA is above a certain threshold, contain both active and inactive
384 clusters with a wide range of activity levels. Thus, their data are consistent with a role for
385 spacer sequences in setting enhancer activity levels.

386 In mammals, few studies involved the systematic large-scale analysis of enhancer variants. In
387 most cases single point mutations were tested, and the resulting effects are expected to be less
388 severe than the randomization approach described here and by Farley et al. (9). Evidence
389 however also exists for a role of spacer sequences in enhancer activity. Kwasnieski et al. (27)

390 reported the dramatic effects of base pair substitutions in the short 52 bp *rhodopsin* enhancer,
391 some of which were located in spacer sequences. In larger enhancers, point mutations had a
392 weaker effect, as reported by Melnikov et al. (28) and Patwardhan et al. (29) and these
393 mutations mostly affected the transcription factor binding sites. It is thus unclear at present
394 whether the impact of spacer sequences is restricted to short enhancers like the elements
395 tested here or the mammalian rhodopsin enhancer, and/or whether they can also impact the
396 activity of less compact elements.

397

398 **Spacer sequences can modulate the affinity of transcription factor binding sites by**
399 **shaping the DNA helix**

400

401 Our results suggest that spacer sequences affect enhancer activity by modulating the *in vitro*
402 binding of transcription factors. Consistently, White et al. (25) showed that binding of the
403 homeodomain protein Crx to clustered motifs was dependent on highly local sequence
404 features such as high GC content. Parallel studies established that the affinity of transcription
405 factors for specific DNA sites is controlled both by nucleotide sequence and DNA helix shape
406 readouts, which are more permissive to variation in specific nucleotide sequence (30). In
407 addition, a comprehensive computational analysis suggested that transcription factor binding
408 is, in part, determined by nucleotides outside of the DNA sequence directly contacted (11,
409 12).

410 Our gel shift experiments provide experimental evidence suggesting that neighbouring base
411 pairs can influence the specific interaction of Ets1/2 protein with the core motif of ETS
412 binding sites by modifying the shape of the DNA helix. A similar observation was done for
413 two yeast transcription factors by Levo et al. (22). Gata4/5/6 binding in contrast, seems to be
414 less sensitive to local variations, which could reflect a greater flexibility of its zinc fingers
415 compared to the alpha helices present in the helix-turn-helix motif of Ets1/2.

416 A finer dissection of the role of flanking base pairs of ETS binding motifs in setting the
417 affinity revealed the importance of position -1 (Figure 5). Wei and co-workers mentioned the
418 absence of a cytosine at this position in the group one Ets family, to which Ets1/2 belongs,
419 and ascribed this to the unique presence in this group of a tyrosine in strand 4 of the DNA
420 binding domain (19). Nevertheless, our Selex-seq data indicate that a cytosine is allowed in
421 this position if it is followed by another cytosine. What could be critical is the presence of a
422 negative roll between position -1 and 1, which is favoured not only by the presence of a
423 purine at -1, but also by two consecutive cytosines. An intriguing possibility would be that a
424 negative roll between bp -1 and 1, which opens the angle between the two base pairs, would
425 facilitate base stacking interaction of the strand 4 tyrosine with the DNA helix. In addition,
426 regions located distal to this extended binding site may also indirectly affect the DNA helix
427 shape of the TFBS, as Ets1/2 *in vitro* affinity is further modulated by sequences outside of
428 bases -1 to 7, a phenomenon particularly striking for variant aR30 (Supplementary Figure 10).
429

430 **Spacer sequences have other roles than modulating the affinity of the transcription**
431 **factor binding sites**

432
433 Altered *in vitro* binding of Ets1/2 and Gata4/5/6 to their binding sites in the randomized
434 variants cannot provide an exclusive explanation for the variability in enhancer activity.
435 Indeed, some inactive 55 bp variants are still binding Ets1/2 and Gata4/5/6 *in vitro* as
436 efficiently as active ones (Figure 3B). Although this effect could in theory be explained by the
437 creation in the randomized spacer sequences of binding sites for factors competing for Ets1/2
438 or Gata4/5/6 binding or for more general repressors of transcription, we did not find any
439 correlation between potential novel sites and enhancer activity (not shown), suggesting
440 additional mechanisms.

441

442 Enhancer sequences *in vivo* act within a complex chromatin environment, in which
443 transcription factors and histones may compete for binding to DNA. Consistently, *in vivo*
444 transcription factor binding assayed by chromatin immunoprecipitation only detects a
445 minority of TFBMs able to bind their transcription factor *in vitro*. It is thus expected that
446 spacers may not solely act by modulating the affinity of transcription factors to the naked
447 DNA helix. Other processes potentially affected by spacer sequences could facilitate
448 nucleosome exclusion (35, 8), DNA flexibility, which could help the formation of large TF
449 complexes on the DNA, or allostery through the DNA helix, whereby fixation of one
450 transcription factor facilitates binding of another transcription factor at a distance (33).

451

452 **Spacer sequences and the robustness of the transcriptional programme**

453

454 One of the most unexpected results of our work is the facility with which a dormant ETS and
455 GATA cluster can be awakened by spacer randomization, which seems in apparent
456 contradiction with the small proportion of active naturally occurring clusters of high affinity
457 ETS and GATA binding sites in the *Ciona* genome (8 and this study): although most synthetic
458 spacers support enhancer function, the majority of natural spacers do not. This enrichment of
459 "inactive spacers" in natural genomes may reflect the need to keep unwanted enhancer
460 activity from appearing.

461 Creation, destruction or compensatory turnover of transcription factor binding sites is a
462 frequent event (34), which could lead to the frequent appearance of clusters of transcription
463 factor binding sites. In the *Drosophila* genome, positive selection contributes to transcription
464 factor binding sites gain and loss, while purifying selection ensures their maintenance.
465 Interestingly, the same trend was found in spacer sequences (35) and Parker et al. (36)
466 provided evidence that the 3D shape of DNA is under selection in vertebrate regulatory
467 regions. Similar selective forces could be at work in the compact genome of *C. intestinalis*

468 (37), and explain that the majority of TFBM clusters feature spacers that ensure their
469 inactivity.

470 Overall, the dependency of enhancer activity on a cross talk between transcription factor
471 binding sites and spacer sequences could buffer against uncontrolled gene expression, thereby
472 ensuring robustness of the developmental programme to sequence mutations.

473

474 **MATERIALS AND METHODS**

475

476 *LacZ reporter assays*

477

478 Mature *Ciona intestinalis* (type B) were provided by the Roscoff Marine Biological station
479 and maintained in natural sea water at 16°C under constant illumination. Eggs were collected,
480 fertilized and dechorionated as previously described (6).

481 Electroporation was performed as previously described (6) using the following parameters:
482 50µg DNA in 50µl H₂O + 200µl D-Mannitol 0,96M ; 50V-16ms pulse, using a Electro Square
483 Porator machine (BTX T820; Harvard Apparatus). Embryos were grown in 0.1% gentamycin
484 ASWH (Artificial Sea Water with HEPES) until their harvest at the 112-cell stage, where Xgal
485 staining is found in every lineage that had expressed Otx so far, recapitulating the expression
486 of the transgene at previous stages (6). Fixation and LacZ staining were performed as
487 described in (6).

488 Where indicated, embryos were treated with a final concentration of 10µM U0126 from the
489 early 16-cell stage (38). Control embryos were treated with the same amount of DMSO,
490 added at the same time point (3µl DMSO in 15ml ASWH per plate). All experiments
491 presented were at least repeated once.

492 At least 100 electroporated embryos were scored for each experiment by counting the % of
493 embryos stained with LacZ in each territory, as this was shown to reflect enhancer activity

494 (39). For each embryo, staining in a6.5 and/or b6.5 lineages, staining in other *Otx* expressing
495 lineages (muscle, a6.7 cell lineage) and activities in territories not expressing *Otx* was
496 retrieved. Enhancer variants driving detectable LacZ expression in less than 5% of stained
497 embryos in all experiments were considered inactive. All values were normalized to the WT
498 a-element activity electroporated in parallel in each experiment.

499 The level of activity in a given cell lineage is considered to be a function of the % of embryos
500 in which X-gal staining is detected in this cell lineage.

501

502 *Gene IDs*

503

504 *Ciona intestinalis Otx* : Gene model ID KH.C4.84 (Unique gene ID: Ciinte.g00006940)

505 *Ciona intestinalis Ets1/2*: Gene model ID KH.C10.113 (Unique gene ID: Ciinte.g00001309)

506 *Ciona intestinalis Gata4/5/6*: Gene model ID KH.L20.1 (Unique gene ID: Ciinte.g00012060)

507

508 *Construct design and molecular cloning*

509

510 All these experiments were carried out using a modified version of the minimal wild-type
511 element, in which a weak GATA binding site (G2; 8) is mutated without quantitative or
512 qualitative impact on the activity of the element.

513

514 *Point mutations in ETS and GATA binding sites motifs*

515

516 The family of GATA transcription factors preferentially binds the consensus “HGATAR” (H
517 = A, C or T, R=G or A) (44; our SELEX data). Therefore, 12 variants of the a-element
518 harbouring all variants of HGATAN at the third GATA position were designed to test both
519 consensus (HGATAR) and non-consensus (HGATAY, Y = C or T) binding site motifs. The

520 Ets family of transcription factors preferentially binds the consensus site “MMGGAWR” (M
521 = A or C; W = A or T; R = G or A), with a higher affinity for “CCGGAWR” (45, 46), which
522 is consistent with *Ciona* SELEX data (Nitta et al., in preparation). “T” at the seventh position
523 was tested as negative control. 21 variants of the a-element were tested harbouring the
524 different combinations MMGGAWD (D = A, G or T) at the second ETS site, with the
525 exception of the MMGGATA combinations as they create an additional overlapping GATA
526 site that could interfere with the ETS site activity and make the interpretation of the results
527 not straightforward.

528 Oligonucleotides were synthesized containing part of Gateway attB1 and attB2 recombination
529 sites in 5’ and 3’ respectively of the different elements we tested. These oligonucleotides were
530 amplified by PCR using attB1F and attB2R primers, then inserted by successive BP and LR
531 reactions in pDONOR221_P1-P2 and pDEST-L1-RFA-L2-bpFOG-LacZ (43).

532

533 *Randomized variants*

534

535 Only six bases per transcription factor binding sites, centered on “GGAA” and “GATA” for
536 ETS and GATA respectively, were kept constant for the a-element variants. 7 bases were kept
537 constant for ETS in randomized N26, N61 and C53 clusters, as it appeared that the 1st base of
538 the ETS site is important for *in vitro* binding.

539 Two nested PCRs were done to amplify the 5’ end of the insert containing an attB1 site, the
540 sequence studied for its enhancer activity and the 5’ end of bpFOG using primers attB1F and
541 P5 R first, then attB1 and P4 R. Three nested PCRs were performed to amplify the 3’ end of
542 the insert containing the other half of bpFOG, the barcode and an attB2 site, using primers P1
543 F and attB2 R first, then P2 F and attB2 R then P3 F and attB2 R. Both fragments were
544 assembled in a last PCR using attB1 F and attB2 R. They were then inserted in pDEST-L1-
545 RFB-L2-LacZ by a one step BP-LR reaction (43)

546

547 *HT-SELEX*

548

549 In SELEX assays, a tagged recombinant protein is incubated in solution with a degenerate
550 mix of double-stranded oligonucleotides, comprising two constant ends of ~20 bases and a
551 central portion of 12 to 24 random bases. The experiments analysed in this article were
552 performed using oligonucleotides with 20 random bases and with bacterially-produced His-
553 tagged transcription factor DNA-binding domains for the *Ciona intestinalis* ELK1/2/3
554 (nucleotides 314-818 of transcript model KH.C8.247.v2.A.SL3-1) and GATA4/5/6
555 (nucleotides 945-1319 of transcript model KH.L20.1.v1.R.ND1-1) proteins. The constant
556 regions of the oligonucleotides contained a barcode, which was unique to each experiment
557 and was used to multiplex oligonucleotide sequencing. The barcode included 6 bp 5' of the
558 randomized portion and 2-3 bp after the randomized region. Protein/DNA complexes were
559 selected by chromatography on a Ni⁺-NTA sepharose (GE Healthcare) column recognizing
560 the histidine tag. Bound oligonucleotides were then amplified by PCR using the constant ends
561 of each oligonucleotide. The binding/chromatography/amplification steps were repeated for 3-
562 7 cycles. After each cycle, the selected oligonucleotides were pooled and sequenced using
563 Illumina Genome Analyzer Iix or HiSeq 2000 sequencer. Raw sequencing data were binned
564 according to barcodes and used for further analyses. Unprocessed raw sequence data are
565 available from the NCBI Short Reads Archive (SRA) (Accession XXXXXX). Before
566 analysing the dataset, the constant region ends with the bar code were removed, leaving just
567 the random portion of 20 bases. Duplicate oligonucleotides were removed from this set as
568 they are most likely artefacts of the PCR amplification.

569

570 *In silico* transcription factor binding site affinity prediction using MOTIF

571

572 We developed a software, called MOTIF, to estimate *in silico* the binding affinity of a
573 transcription factor to a DNA sequence, based on SELEX-seq data (also called HT-SELEX),
574 represented by the enrichment values of all 4096 6-mers present in the variable portion of the
575 sequenced oligonucleotides bound to the transcription factor in the HT-selex procedure. The
576 algorithm is as follows.

577 In a random set of oligonucleotides, k-mer frequencies will be distributed uniformly. HT-
578 SELEX oligonucleotides are not random, as the method enriches for oligonucleotides bound
579 to the transcription factor. The k-mer frequency distribution will thus become skewed, and the
580 DNA-binding specificity of the transcription factor can be represented by an enrichment value
581 for each of the k-mers considered. 6-mers were used here since 4,096 k-mers provides a
582 sufficient number of k-mers without becoming sparse considering the depth of the
583 sequencing. k-mer frequencies are determined by counting the occurrences of each k-mer in
584 the set of unique oligonucleotides. To obtain an enrichment value, the observed count of each
585 k-mer in the sequenced oligonucleotides, *obs*, are normalized using the expected count, *exp*,
586 of each k-mer based on the number of sequenced oligonucleotides, *n*, with a variable
587 oligonucleotide length of *d*, as shown in equation 1.

$$588 \quad exp = \frac{n * (d - k)}{4^k} \quad (1)$$

589 The enrichment score, *e*, was calculated as shown in equation 2.

$$590 \quad e = \log_{10} \left(\frac{obs}{exp} \right) \quad (2).$$

591
592 The synthesis method used to produce the original random pool of oligonucleotides is often
593 biased, enriching certain k-mers over others. To correct for this bias, the enrichments are
594 adjusted by the enrichment in the background set, shown in equation 3.

$$595 \quad e_{adj} = e_{raw} - e_{background} \quad (3)$$

596 Many transcription factors recognize motifs longer than 6 bases. MOTIF thus associate to
597 each base of the analysed DNA sequence a score predicting the binding of a transcription
598 factor to the 8-mer starting at this base (Supplementary Figure 2). It corresponds to the sum of
599 the 6-mer enrichments scores of the three 6-mers contained in each 8-mers.

600

601 *Selection of the 14 ETS/GATA genomic clusters tested in vivo by electroporation*

602

603 101 clusters containing at least 2 sites ETS and 2 sites GATA were identified in *Ciona*
604 *intestinalis* genome, using SECOMOD, and a very relaxed consensus for the transcription
605 factor binding sites sequences (as described in 8). We then looked for clusters of maximum
606 140 bp with at least 5 bp between two consecutive transcription factor binding sites. 55
607 conserved clusters were identified by (8). We tested the activity of an additional eight non-
608 conserved and six conserved clusters in *C. savignyi*.

609 The 14 tested clusters contain 2 ETS and GATA sites with high MOTIF scores. Their
610 sequences are listed in Supp. Table 1.

611

612 *2-colour Fluorescent Electrophoretic Mobility Shift Assay*

613

614 The DNA-binding domains of Ets1/2 (Ensembl ID: ENSCINT00000011848), i.e. aa 581-708,
615 and GATA4/5/6 (Ensembl ID: ENSCINP00000009159), i.e. aa 291-415, were identified by
616 homology to domains of orthologous human proteins used in the crystallographic 3D
617 structure determination (Ets1, MMDB ID: 62790 and GATA1, MMDB ID: 106606). The
618 corresponding DNA sequences were amplified by PCR from the cDNAs (44) and cloned in
619 the expression vector pETG20A (EMBL Protein Expression and Purification Facility) by
620 Gateway technology (Life Sciences). N-terminally poly-His-thioredoxin tagged recombinant

621 proteins were produced in Rosetta-pLys-R strain and purified on Nickel Agarose columns as
622 described in (45).

623 Enhancer DNA fragments were produced by PCR from the plasmids used for the LacZ
624 reporter assays using Cy5 or Alexia 488-5' labelled 19 nt primers (MWG Eurofins) flanking
625 the enhancer sequences, i.e. TTGTACAAAAAAGCAGGCT for the forward and
626 GGTACAATACACGAAGCTT for the reverse primer. DNA fragments containing unique
627 transcription factor binding sites were synthesized directly (MWG Eurofins) and 5'-terminally
628 labelled with Cy5 or Cy3 for the internal control on one strand.

629 The reaction conditions for the GS experiments were adapted from Hashimoto & Ware,
630 (1995). Labelled DNA was incubated at 0.015 μ M with recombinant Ets1/2 at 0.2 μ M or
631 Gata4/5/6 at 0.1 μ M during 15 minutes at room temperature in 25mM Hepes pH7.9, 50mM
632 KCl, 0.5 mM EDTA, 10% glycerol, 0.5mM di-thiothreitol and 100 μ g/ml poly(dI-dC) and
633 loaded on a 6% polyacrylamide gel in 0.5 % TAE, which was run at 10V/cm. The
634 fluorescence was registered with an Amersham Imager 600 (General Electric) and quantified
635 with the software provided by the supplier.

636 To have a better control over the experimental conditions we included an internal control: the
637 randomized DNA fragments are fluorescently labelled with Cy5 and mixed with an equimolar
638 amount of control DNA fragment labelled with Alexia 488 or Cy3. Relative affinities Y are
639 quantified by reporting the fraction of shifted randomized DNA fragments to that of control
640 fragment (21) (Supplementary Figure 4).

641

642 **ACKNOWLEDGEMENTS**

643 We thank Dylan Da Cunha for help with the experiments and the Centre National pour la
644 Recherche Scientifique, l'Université de Montpellier and l'Agence Nationale pour la Recherche
645 (Grants Chor-Reg-Net ANR2005 NT05-2_42083; Chor-Evo-Net ANR2008 Blan 067 91; and
646 TED ANR-13-BSV2-0011-01) for support. C. Cambillau, C. Dantec, P. Lemaire, J. Piette, U.

647 Rothbacher, and R. Vincentelli were CNRS employees. M. Guérout Bellone was supported
648 by a doctoral contract from the University of Montpellier, K. R. Nitta and E. Jacox were
649 supported by ANR grants to PL, a CNRS post-doctoral contract (KRN) and a Marie Curie
650 Incoming International Fellowship (PIIF-GA-2010-272840, CisRegLogic, EJ).

651

652 **COMPETING INTEREST**

653 The authors declare no competing interest

654

655 **REFERENCES**

- 656 1. Miguel-Escalada I, Pasquali L, Ferrer J. Transcriptional enhancers: functional insights
657 and role in human disease. *Curr Opin Genet Dev.* 2015;33:71–6.
- 658 2. Douglas AT, Hill RD. Variation in vertebrate cis-regulatory elements in evolution and
659 disease. *Transcription.* 2014;5(3):e28848.
- 660 3. Arnone MI, Davidson EH. The hardwiring of development: organization and function
661 of genomic regulatory systems. *Development.* 1997;124(10):1851–64.
- 662 4. Borok MJ, Tran DA, Ho MCW, Drewell RA. Dissecting the regulatory switches of
663 development: lessons from enhancer evolution in *Drosophila*. *Development.*
664 2010;137(1):5–13.
- 665 5. Smith RP, Taher L, Patwardhan RP, Kim MJ, Inoue F, Shendure J, et al. Massively
666 parallel decoding of mammalian regulatory sequences supports a flexible
667 organizational model. *Nat Genet.* 2013;45(9):1021–8.
- 668 6. Bertrand V, Hudson C, Caillol D, Popovici C, Lemaire P. Neural tissue in ascidian
669 embryos is induced by FGF9/16/20, acting via a combination of maternal GATA and
670 Ets transcription factors. *Cell.* 2003;115(5):615–27.
- 671 7. Rothbacher U, Bertrand V, Lamy C, Lemaire P. A combinatorial code of maternal
672 GATA, Ets and beta-catenin-TCF transcription factors specifies and patterns the early
673 ascidian ectoderm. *Development.* 2007;134(22):4023–32.
- 674 8. Khoueiry P, Rothbacher U, Ohtsuka Y, Daian F, Frangulian E, Roure A, et al. A cis-
675 regulatory signature in ascidians and flies, independent of transcription factor binding
676 sites. *Curr Biol.* 2010;20(9):792–802.
- 677 9. Farley EK, Olson KM, Zhang W, Brandt AJ, Rokhsar DS, Levine MS.
678 Suboptimization of developmental enhancers. *Science.* 2015;350(6258):325–8.
- 679 10. Yáñez-Cuna JO, Arnold CD, Stampfel G, Boryń LM, Gerlach D, Rath M, et al.
680 Dissection of thousands of cell type-specific enhancers identifies dinucleotide repeat
681 motifs as general enhancer features. *Genome Res.* 2014;24(7):1147–56.
- 682 11. Dror I, Golan T, Levy C, Rohs R, Mandel-Gutfreund Y. A widespread role of the motif
683 environment in transcription factor binding across diverse protein families. *Genome*
684 *Res.* 2015;25(9):1268–80.
- 685 12. Gordân R, Shen N, Dror I, Zhou T, Horton J, Rohs R, et al. Genomic regions flanking
686 E-box binding sites influence DNA binding specificity of bHLH transcription factors

- 687 through DNA shape. *Cell Rep.* 2013;3(4):1093–104.
- 688 13. Nitta KR, Jolma A, Yin Y, Morgunova E, Kivioja T, Akhtar J, et al. Conservation of
689 transcription factor binding specificities across 600 million years of bilateria evolution.
690 *Elife.* 2015;4: e04837.
- 691 14. Slattery M, Zhou T, Yang L, Dantas Machado AC, Gordân R, Rohs R. Absence of a
692 simple code: how transcription factors read the genome. *Trends Biochem Sci.*
693 2014;39(9):381–99.
- 694 15. Bates DL, Chen Y, Kim G, Guo L, Chen L. Crystal structures of multiple GATA zinc
695 fingers bound to DNA reveal new insights into DNA recognition and self-association
696 by GATA. *J Mol Biol.* 2008;381(5):1292–306.
- 697 16. Chen Y, Bates DL, Dey R, Chen P-H, Machado ACD, Laird-Offringa IA, et al. DNA
698 binding by GATA transcription factor suggests mechanisms of DNA looping and long-
699 range gene regulation. *Cell Rep.* 2012;2(5):1197–206.
- 700 17. Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ, et al.
701 JASPAR 2014: An extensively expanded and updated open-access database of
702 transcription factor binding profiles. *Nucleic Acids Res.* 2014;42(D1).
- 703 18. Werner MH, Clore GM, Fisher CL, Fisher RJ, Trinh L, Shiloach J, et al. Correction of
704 the NMR structure of the ETS1/DNA complex. *J Biomol NMR.* 1997;10(4):317–28.
- 705 19. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide
706 analysis of ETS-family DNA-binding in vitro and in vivo. *EMBO J. Nature Publishing
707 Group;* 2010;29(13):2147–60.
- 708 20. Alquraishi M, Tang S, Xia X. An affinity-structure database of helix-turn- helix : DNA
709 complexes with a universal coordinate system. *BMC Bioinformatics. BMC
710 Bioinformatics;* 2015;16:390.
- 711 21. Man TK, Stormo GD. Non-independence of Mnt repressor-operator interaction
712 determined by a new quantitative multiple fluorescence relative affinity (QuMFRA)
713 assay. *Nucleic Acids Res.* 2001;29(12):2471–8.
- 714 22. Levo M, Zalckvar E, Sharon E, Carolina A, Machado D, Lotam-pompan M, et al.
715 Unraveling determinants of transcription factor binding outside the core binding site.
716 *Genome Res.* 2015;1–41.
- 717 23. Zhou T, Yang L, Lu Y, Dror I, Dantas Machado AC, Ghane T, et al. DNASHape: a
718 method for the high-throughput prediction of DNA structural features on a genomic
719 scale. *Nucleic Acids Res.* 2013;41(Web Server issue):56–62.
- 720 24. Wunderlich Z, Mirny L a. Different gene regulation strategies revealed by analysis of
721 binding motifs. *Trends Genet.* 2009;25(10):434–40.
- 722 25. Yan J, Enge M, Whittington T, Dave K, Liu J, Sur I, et al. Transcription factor binding
723 in human cells occurs in dense clusters formed around cohesin anchor sites. *Cell.*
724 2013;154(4):801–13.
- 725 26. White M a., Myers C a., Corbo JC, Cohen B a. Massively parallel in vivo enhancer
726 assay reveals that highly local features determine the cis-regulatory function of ChIP-
727 seq peaks. *Proc Natl Acad Sci.* 2013;1–6.
- 728 27. Kwasnieski JC, Mogno I, Myers C a, Corbo JC, Cohen B a. Complex effects of
729 nucleotide variants in a mammalian cis-regulatory element. *Proc Natl Acad Sci U S A.*
730 2012;109(47):19498-503.
- 731 28. Melnikov A, Murugan A, Zhang X, Tesileanu T, Wang L, Rogov P, et al. Systematic
732 dissection and optimization of inducible enhancers in human cells using a massively
733 parallel reporter assay. *Nat Biotechnol. Nature Publishing Group;* 2012;30(3):271–7.
- 734 29. Patwardhan RP, Hiatt JB, Witten DM, Kim MJ, Smith RP, May D, et al. Massively
735 parallel functional dissection of mammalian enhancers in vivo. *Nat Biotechnol.* 2012
736 ;30(3):265–70.
- 737 30. Rohs R, Jin X, West SM, Joshi R, Honig B, Mann RS. Origins of specificity in protein-

- 738 DNA recognition. *Annu Rev Biochem.* 2010;79:233–69.
- 739 31. Jolma A, Yan J, Whittington T, Toivonen J, Nitta KR, Rastas P, et al. DNA-binding
740 specificities of human transcription factors. *Cell.* 2013;152(1–2):327–39.
- 741 32. Barrière A, Gordon KL, Ruvinsky I. Distinct functional constraints partition sequence
742 conservation in a cis-regulatory element. *PLoS Genet.* 2011;7(6):e1002095.
- 743 33. Kim S, Broströmer E, Xing D, Jin J, Chong S, Ge H, et al. Probing allostery through
744 DNA. *Science.* 2013;339(6121):816–9.
- 745 34. Bradley RK, Li X, Trapnell C, Davidson S, Pachter L, Cheng H, et al. Binding Site
746 Turnover Produces Pervasive Quantitative Changes in Transcription Factor Binding
747 between Closely Related *Drosophila* Species. *PLoS Biol.* 2010;8(3):e1000343.
- 748 35. He BZ, Holloway AK, Maerkl SJ, Kreitman M. Does positive selection drive
749 transcription factor binding site turnover? A test with *Drosophila* cis-regulatory
750 modules. *PLoS Genet.* 2011;7(4):e1002053.
- 751 36. Parker S, Hansen L, Abaan H, Tullius T, Margulies E. Local DNA Topography
752 Correlates with Functional Noncoding Regions of the Human Genome. *Science.*
753 2009;324:389–92.
- 754 37. Dehal P, Satou Y, Campbell RK, Chapman J, Degnan B, De Tomaso A, et al. The draft
755 genome of *Ciona intestinalis*: insights into chordate and vertebrate origins. *Science.*
756 2002;298(5601):2157–67.
- 757 38. Hudson C, Darras S, Caillol D, Yasuo H, Lemaire P. A conserved role for the MEK
758 signalling pathway in neural tissue specification and posteriorisation in the invertebrate
759 chordate, the ascidian *Ciona intestinalis*. *Development.* 2003;130(1):147–59.
- 760 39. Brown CD, Johnson DS, Sidow A. Functional architecture and evolution of
761 transcriptional elements that drive gene coexpression. *Science.* 2007;317(5844):1557–
762 60.
- 763 40. Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors.
764 *Mol Cell Biol.* 1993;13(7):3999–4010.
- 765 41. Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, Lupien M, et al.
766 Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation
767 of core components of the gene regulation machinery. *Genome Res.*
768 2009;19(11):1963–73.
- 769 42. Wasylyk C, Kerckaert JP, Wasylyk B. A novel modulator domain of Ets transcription
770 factors. *Genes Dev.* 1992;6(6):965–74.
- 771 43. Roure A, Rothbacher U, Robin F, Kalmar E, Ferone G, Lamy C, et al. A multicassette
772 Gateway vector set for high throughput and comparative analyses in *ciona* and
773 vertebrate embryos. *PLoS One.* 2007;2(9):e916.
- 774 44. Gilchrist MJ, Sobral D, Khoueiry P, Daian F, Laporte B, Patrushev I, et al. A pipeline
775 for the systematic identification of non-redundant full-ORF cDNAs for polymorphic
776 and evolutionary divergent genomes: Application to the ascidian *Ciona intestinalis*.
777 *Dev Biol.* 2015;404(2):1–15.
- 778 45. Vincentelli R, Cimino A, Geerlof A, Kubo A, Satou Y, Cambillau C. High-throughput
779 protein expression screening and purification in *Escherichia coli*. *Methods.*
780 2011;55(1):65–72.
- 781 46. Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within
782 the promoter of the platelet glycoprotein Ib α gene. *J Biol Chem.* 1995;270(41):24532–
783 9.
- 784
- 785

786 **SUPPLEMENTARY DATA**

787 **Supplementary Figure 1: DNA residues contacted by Gata3 and Ets1**

788 The logo is deduced from our Selex-seq data (for *C. intestinalis* Gata4/5/6 in (A) and Elk3 in
789 (B). Contacts are deduced from the crystal structure-data of human Gata3-DNA complex (A;
790 Chen et al. 2012) and these compiled by Wei et al. (2010) on mammalian Ets1-DNA complex
791 (B). Conserved amino acids of *C. intestinalis* in contact with DNA are in bold; contacts with
792 the base pairs are in black, contacts with water molecules in blue and with the sugar-
793 phosphate backbone in green.

794

795 **Supplementary Figure 2: *In silico* k-mer binding affinity calculations with MOTIF**

796 Randomly synthesised oligonucleotides binding the *in vitro* produced DNA-binding domain
797 of the transcription factors were enriched by the Selex-seq procedure. for each k-mer, its
798 enrichment e was calculated as indicated in (B). The MOTIF score for each octamer,
799 reflecting *in vitro* transcription factor binding affinity, is obtained by summing 3 consecutive
800 6-mer scores as shown in (A).

801

802 **Supplementary Figure 3: Moderate correlation between *in silico* binding predictions
803 and *in vivo* activity**

804 A) a-element sequence describing ETS (blue) and GATA (green) site mutations tested *in vivo*.
805 B) Comparison of *in vivo* enhancer activity and *in silico* predicted binding calculated for E2
806 octamer (MOTIF score). Each point corresponds to an ETS site variant individual *in vivo*
807 experiment. C) Comparison of *in vivo* enhancer activity and *in silico* predicted binding
808 calculated for G3. Each point corresponds to a GATA site variant individual *in vivo*
809 experiment (triangles and circles respectively correspond to experiments 1 and 2 from Figure
810 1). Colours correspond to that of the last base and yellow circles correspond to the WT a-
811 element.

812

813 **Supplementary Figure 4: Relative affinities are quantified by QuMFRA**

814 A) Gel shifts of the a-element with the DNA binding domains (DBD) of Gata4/5/6 (red),
815 Ets1/2 (blue) separately (left) or combined (right). B-C) Quantification of the affinity of
816 Ets1/2 and Gata4/5/6 for nine individual a-element mutants. Equimolar amounts of Att488
817 labelled WT a-element (B) and Cy5 labelled mutant or randomized variants (C) were
818 incubated with recombinant Ets1/2 and Gata4/5/6 DBD and loaded on a 6% PAGE as
819 explained in materials and methods. Panels B and C show the same gel imaged with the two
820 wavelengths. The fluorescence of the shifted bands S and the total fluorescence T was
821 quantified with a Amersham Imager 600. The relative affinity Y, shown on main figures, was
822 calculated using the formula $Y=(S_n/T_n)*(T_c /S_c)$.

823

824 **Supplementary Figure 5: Comparison between *in silico* and *in vitro* relative binding**
825 **affinities for tested mutants**

826 Relative *in silico* MOTIF scores (red bars) and *in vitro* binding affinities (purple bars)
827 determined by gel shift assays for the indicated mutants. ETS is in (A) and GATA in (B).

828

829 **Supplementary Figure 6: DNA sequence alignment of randomized variants for the a-**
830 **element, the active N26 cluster and the inactive N61 and C53 clusters**

831 DNA sequences were aligned using SeaView. ETS binding sites are represented by blue, and
832 GATA binding sites by green arrowheads. a-element is in (A), N26 in (B), N61 in (C) and
833 C53 in (D).

834

835 **Supplementary Figure 7: Some randomized variants have a broader activity pattern**
836 **than the a-element**

837 Normalized *in vivo* enhancer activity is determined for WT and randomized variants of the a-
838 element. The percentage of embryos where LacZ staining was only detected in a6.5 and b6.5
839 progeny is shown in blue, that where activity was detected in other cells appear in different
840 colours corresponding to the cells drawn in dorsal and ventral views of a 112 cell-embryo.
841 Activity in cells other than a6.5/b6.5 progeny was always associated with activity in a6.5
842 and/or b6.5 progeny.

843

844 **Supplementary Figure 8: Response of randomized variants to the FGF-signalling**
845 **pathway**

846 Relative enhancer activities in control embryos or embryos treated with the MEK kinase
847 inhibitor U0126 at the 16-cell stage. Enhancer activity relative to WT a-element is indicated
848 in blue for a6.5/b6.5 only and in red for additional cells.

849

850 **Supplementary Figure 9: Comparison of *in silico* predicted and *in vitro* relative binding**
851 **affinities of active versus inactive a-element variants**

852 A) Upper=Relative sum of the MOTIF score for the ETS binding sites compared to WT of the
853 variants of figure 3 (paired t-test for the inactive versus active variants, p=0.06651).
854 Lower=Relative sum of the MOTIF score for the GATA binding sites compared to WT of the
855 variants of figure 3 (paired t-test for the inactive versus active variants, p=0.3789). B) Upper=
856 Relative *in vitro* binding of Ets1/2 compared to the WT a-element of the same revertants as in
857 (A). The two populations are different (paired t-test, p=0.01737). Lower=Relative *in vitro*
858 binding of Gata4/5/6 compared to the WT a-element of the same revertants as in (A). The two
859 populations are different (paired t-test, p=0.05347)

860

861 **Supplementary Figure 10: Affinity of Gata4/5/6 and Ets1/2 for isolated sites compared**
862 **to the complete 55 bp a-element variants**

863 Relative *in vitro* transcription factor binding affinities are shown for the complete variants
864 above the corresponding isolated GATA (A) or ETS (B) sites. Dark blue represents the
865 relative contribution of the upper band corresponding to binding of two molecules in the gel
866 shift experiments.

867

868 **Supplementary Figure 11: Nonamer scores are better predictors of Ets1/2 affinity than**
869 **octamer scores**

870 *In silico* MOTIF Scores derived from the Selex-seq data were plotted against the *in vitro*
871 relative Ets1/2 affinity determined by gel shift experiments with 30-mers centered on the
872 GGAA motif. The scores were calculated for respectively octa- or nonamers as represented by
873 boxes above the graphs.

874

875 **Supplementary Figure 12: Further addition of variant base pairs to the ETS decamer**
876 **modulates the affinity for Ets1/2**

877 Comparison of relative *in vitro* Ets1/2 binding affinities of indicated E1 or E2 decamers in
878 their original environment (l) or that of the E2 site of the a-element (s) as indicated above the
879 diagram. Affinity is relative to WT_E2.

880

881 **Supplementary Table 1: Sequence and genome coordinates of genomic ETS and GATA**
882 **clusters conserved (C) and non-conserved (N) in *Ciona savignyi* genome**

883

884 **Supplementary Table 2: Sequences of the a-element, N26, N62 and C53_Opt genomic**
885 **clusters and their randomized variants**

886

887 **Supplementary Table 3: Sequences of the oligonucleotides used for the gel shift**
888 **experiments**

889

890

891